Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Explores AI Content Marketplace With Media Publishers 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
West Lafayette, Ind., Feb. 22, 2018 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in pediatric osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
